Cited by 490Schizophrenia research and treatmentPharmacology and Obesity TreatmentEating Disorders and Behaviors

The DOI matches its Crossref record; 363 of the 363 references it cites were found in a registry or an index.

Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis

Open access

Bak, Maarten, Fransen, Annemarie, Janssen, Jouke, van Os, Jim, Drukker, Marjan·2014·PLoS ONE

DOI 10.1371/journal.pone.0094112PMC PMC3998960

Open this paper in CoChat — free account Open PDF

Abstract

INTRODUCTION: Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses generally are restricted to second generation antipsychotics (SGA) and do not stratify for duration of AP use. It is hypothesised that patients gain more weight if duration of AP use is longer. METHOD: A meta-analysis was conducted of clinical trials of AP that reported weight change. Outcome measures were body weight change, change in BMI and clinically relevant weight change (7% weight gain or loss). Duration of AP-use was stratified as follows: ≤6 weeks, 6-16 weeks, 16-38 weeks and >38 weeks. Forest plots stratified by AP as well as by duration of use were generated and results were summarised in figures. RESULTS: 307 articles met inclusion criteria. The majority were AP switch studies. Almost all AP showed a degree of weight gain after prolonged use, except for amisulpride, aripiprazole and ziprasidone, for which prolonged exposure resulted in negligible weight change. The level of weight gain per AP varied from discrete to severe. Contrary to expectations, switch of AP did not result in weight loss for amisulpride, aripiprazole or ziprasidone. In AP-naive patients, weight gain was much more pronounced for all AP. CONCLUSION: Given prolonged exposure, virtually all AP are associated with weight gain. The rational of switching AP to achieve weight reduction may be overrated. In AP-naive patients, weight gain is more pronounced.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0094112

Cites

363 of 363 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Prisma Checklist flow diagram.CC BY · PubMed Central

Figure 2 Weight change (in kg) per period per antipsychotic medication.CC BY · PubMed Central

Figure 3 Weight change (kg) per period only including AP-naive samples.CC BY · PubMed Central

Figure 4 BMI change per period.CC BY · PubMed Central

Figure 5 BMI change in AP naive patients per time period.CC BY · PubMed Central

Figure 6 Proportion of weight increase per antipsychotic per time period.CC BY · PubMed Central

Figure 7 Proportion of weight increase in AP naïve.CC BY · PubMed Central

Figure 8 Proportion of weight reduction.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 6×
“In addition, Allison [19] suggested to study clinically significant weight gain and weight loss and provided a definition.”
BackgroundMethodResultInfluential
A Systematic Review of Mortality in Schizophrenia: Is the Differential Mortality Gap Worsening Over Time?
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065 · cited 1×
“Compared to the general population, the risk of developing cardiovascular illness is doubled and more than five times higher for endocrine disease [12,14].”
Background
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 1×
“Indeed some reviews address this issue although restricted to only schizophrenia and bipolar disorder [27,61].”
Background
Excess Mortality in Bipolar and Unipolar Disorder in Sweden
Ösby, U., Brandt, L., Correia, N., Ekbom, A., & Sparén, P. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.844 · Cited by 1,120 · cited 1×
“6 in women [15].”
Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & Binder, M. D. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,120 · cited 1×
“Within the group of SMI, the risk for weight gain is more enhanced for schizophrenia than for bipolar disorder [55,56].”
Background
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
McEvoy, J. M., Lieberman, J. A., Stroup, T. S., Thomas, S., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.4.600 · Cited by 1,013
A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk—a review of the literature
Huxley, R., Mendis, S., Zheleznyakov, E., Reddy, S., & Chan, J. C. N. (2009) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2009.68 · Cited by 772 · cited 1×
“Overweight and particularly obesity predicts cardiovascular risk, metabolic syndrome (MS) and diabetes mellitus type 2 (DM-II) [1–5] as well as an increased risk for cancer [6,7].”
Background
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D., & GOFF, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.975 · Cited by 699 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Metabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634 · cited 1×
“Within the group of SMI, the risk for weight gain is more enhanced for schizophrenia than for bipolar disorder [55,56].”
Background
Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder
Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., ZIMBROFF, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder
Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M. W., Stock, E. G., Stringfellow, J., Ingenito, G. G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 592 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression: A Double-blind, Placebo-controlled Study (The BOLDER II Study)
Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.790 · Cited by 556
Efficacy of Olanzapine in Acute Bipolar Mania A Double-blind, Placebo-Controlled Study
Tohen, M. F. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.9.841 · Cited by 539
Novel antipsychotics: comparison of weight gain liabilities.
Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999) · PubMed · Cited by 523
A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania
Keck, P. E., Marcus, R. N., Tourkodimitris, S., Ali, M. W., Liebeskind, A., Saha, A. R., Ingenito, G. G., & Aripiprazole Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1651 · Cited by 501 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials
Marder, S. R., McQuade, R. D., Stock, E. G., Kaplita, S., Marcus, R. N., Safferman, A. Z., Saha, A. R., Ali, M. W., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467
Depression and Risk of Mortality in People with Diabetes Mellitus: A Systematic Review and Meta-Analysis
van Dooren, F. E. P., Nefs, G., Schram, M. T., Verhey, F. R. J., Denollet, J., & Pouwer, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057058 · Cited by 441
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Thomas, S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., DAVIS, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.4.611 · Cited by 431
Antipsychotic medications: metabolic and cardiovascular risk.
Newcomer, J. W. (2007) · PubMed · Cited by 416
Obesity Among Those with Mental Disorders
Allison, D. B., Newcomer, J. W., Dunn, A. L., Blumenthal, J. A., Fabricatore, A. N., Daumit, G. L., Cope, M. B., Riley, W. T., Vreeland, B., Hibbeln, J. R., et al. (2009) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2008.11.020 · Cited by 403 · cited 1×
“Indeed some reviews address this issue although restricted to only schizophrenia and bipolar disorder [27,61].”
Background
Novel Antipsychotics
Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0602 · Cited by 392 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Schooler, N. R., Rabinowitz, J., Davidson, M., Emsley, R. A., Harvey, P. D., Kopala, L. C., McGorry, P. D., Hove, I. V., Eerdekens, M., Swyzen, W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.947 · Cited by 351 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective Disorder
Conley, R. R., & Mahmoud, R. A. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.765 · Cited by 336 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges
Fleishhacker, W. W., Cetkovich-Bakmas, M., De Hert, M., Hennekens, C. H., Lambert, M., Leucht, S., Maj, M., McIntyre, R. S., Naber, D., Newcomer, J. W., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0401 · Cited by 328 · cited 2×
“In general, it is concluded that AP add to the increased mortality risk of people with SMI either through direct cardio toxic effects or by impacting on weight gain [8,18].”
Background
Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients With Bipolar I Disorder Responding to Acute Treatment With Olanzapine
Tohen, M., Calabrese, J. R., Sachs, G. S., Banov, M. D., Detke, H. C., Risser, R., Baker, R. W., Chou, J. C.-Y., & Bowden, C. L. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.247 · Cited by 317
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001) · PubMed · Cited by 317
Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials
Álvarez‐Jiménez, M., Hetrick, S. E., González‐Blanch, C., Gleeson, J., & McGorry, P. D. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.042853 · Cited by 315 · cited 1×
“Psychiatrists should keep in mind that switching antipsychotics requires monitoring and evaluation [51] and may benefit from concurrent non-pharmacological interventions [58,59].”
Background
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315 · cited 2×
“Overweight and particularly obesity predicts cardiovascular risk, metabolic syndrome (MS) and diabetes mellitus type 2 (DM-II) [1–5] as well as an increased risk for cancer [6,7].”
Background
Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia
Pigott, T. A., Carson, W. H., Saha, A. R., Torbeyns, A. F., Stock, E. G., Ingenito, G. G., & Aripiprazole Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0910 · Cited by 309 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
Kasper, S. F., Lerman, M. N., McQuade, R. D., Saha, A. R., Carson, W. H., Ali, M. W., Archibald, D., Ingenito, G. G., Marcus, R. N., & Pigott, T. A. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003651 · Cited by 309 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial☆
Kane, J. M., Cañas, F., Kramer, M. L., Ford, L., Gassmann-Mayer, C., Lim, P., & Eerdekens, M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.012 · Cited by 297
Factors Influencing Acute Weight Change in Patients With Schizophrenia Treated With Olanzapine, Haloperidol, or Risperidone
Basson, B. R., Kinon, B. J., Taylor, C. C., Szymanski, K. A., Gilmore, J. A., & Tollefson, G. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0404 · Cited by 278 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq042 · Cited by 275 · cited 1×
“A direct comparison between AP to calculate differences between the various AP was only presented by Rummel-Kluge, performing a head-to-head comparison [25] Leucht and colleagues [35] also showed that (i) all AP are associated with at least some weight gain compared with placebo and (ii) that olanzapine and clozapine…”
Result
Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders
Álvarez‐Jiménez, M., González‐Blanch, C., Crespo‐Facorro, B., Hetrick, S. E., Rodríguez-Sánchez, J. M., Pérez‐Iglesias, R., & Vázquez‐Barquero, J. L. (2008) · CNS Drugs · doi:10.2165/00023210-200822070-00002 · Cited by 271 · cited 3×
“Another problem is that outcome of studies and meta-analyses are contaminated by two factors: (i) mix of study duration (short and long term studies) whereas effects on weight are delayed and (ii) no distinction is made between first episode of drug naive patients and chronic patients [20].”
BackgroundMethodResult
Long-Term Olanzapine Treatment
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0204 · Cited by 269 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities
McIntyre, R. S., McCann, S., & Kennedy, S. H. (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674370104600308 · Cited by 261 · cited 2×
“Subsequent metaanalyses confirmed the finding that most AP contributes to weight gain [20–26].”
Background
Long-Term Efficacy and Safety of Iloperidone
Kane, J. M., Lauriello, J., LASKA, E. M., Marino, M. E. D., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318169cca7 · Cited by 251 · cited 1×
“7 (, 6 wk, n = 1239) [45], levomepromazine 4.”
Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression: Results of 2 Randomized, Placebo-Controlled Studies
Thase, M. E., Jonas, A., Khan, A., Bowden, C. L., Wu, X., McQuade, R. D., Carson, W. H., Marcus, R. N., & Owen, R. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181618eb4 · Cited by 251 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Treatment of Female Borderline Personality Disorder Patients
Zanarini, M. C., & Frankenburg, F. R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1103 · Cited by 251 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study
Davidson, M., Emsley, R. A., Kramer, M. L., Ford, L., Pan, G., Lim, P., & Eerdekens, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.003 · Cited by 249 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
Binder, M. D., Schreurs, V., Sweers, K., Eyck, D. V., Hanssens, L., Šinko, S., Wampers, M., Scheen, A. J., Peuskens, J., & van Winkel, R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.028 · Cited by 247
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study
Sachs, G. S., Sanchez, R., Marcus, R. N., Stock, E. G., McQuade, R. D., Carson, W. H., Abou-Gharbia, N., Impellizzeri, C., Kaplita, S., Rollin, L., et al. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106059693 · Cited by 245
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade, R. D., Stock, E. G., Marcus, R. N., Jody, D. N., Abou-Gharbia, N., Vanveggel, S., Archibald, D., & Carson, W. H. (2004) · PubMed · Cited by 244
Weight Gain Associated With Increased Food Intake and Low Habitual Activity Levels in Male Adolescent Schizophrenic Inpatients Treated With Olanzapine
Gothelf, D., Falk, B., Singer, P., Kairi, M., Phillip, M., Zigel, L., Poraz, I., Frishman, S., Constantini, N., Zalsman, G., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1055 · Cited by 242 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole Monotherapy for Maintenance Therapy in Bipolar I Disorder: A 100-Week, Double-Blind Study Versus Placebo
Keck, P. E., & Calabrese, J. R. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1003 · Cited by 238 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Increases Weight and Serum Triglyceride Levels
Osser, D. N., Najarian, D. M., & Dufresne, R. L. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1109 · Cited by 231 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Waist circumference and waist/hip ratio in relation to all-cause mortality, cancer and sleep apnea
Seidell, J. C. (2009) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2009.71 · Cited by 231
A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania
Tohen, M. F., Goldberg, J. F., Arrillaga, A. M. G.-P., Azorin, J. M., Vieta, E., Hardy-Baylé, M. C., Lawson, W. B., Emsley, R. A., Zhang, F., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1218 · Cited by 229 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study
Marder, S. R., Kramer, M. L., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M., & Lowy, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.017 · Cited by 228 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Risperidone Versus Pimozide in Tourette's Disorder
Bruggeman, R., van der Linden, C., Buitelaar, J. K., Gericke, G. S., Hawkridge, S. M., & Temlett, J. A. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0111 · Cited by 224 · cited 1×
“9 (6– 16 wk, n = 24) [48] and zuclopentixol 0.”
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224 · cited 7×
“Long term use of antipsychotics (AP) is associated with increased mortality risk in people with SMI [16,17].”
BackgroundInfluential
Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder
Soler, J., Pascual, J. C., Campins, J., Barrachina, J., Puigdemont, D., Alvarez, E., & Pérez, V. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1221 · Cited by 224 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia
Yang, J.-W., Bahk, W., Cho, H.-S., Jeon, Y., Jon, D., Jung, H., Kim, C., Kim, H., Kim, Y., Kim, Y. H., et al. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181dcda50 · Cited by 220 · cited 1×
“48 (6–16 wk, n = 92) [43], fluphenazine 22.”
Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia
Kramer, M. L., Simpson, G. M., Mačiulis, V., Kushner, S. F., Vijapurkar, U., Lim, P., & Eerdekens, M. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802dda4a · Cited by 219 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia
Enger, C. L., Weatherby, L. B., Reynolds, R. F., Glasser, D. B., & Walker, A. M. (2003) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000105996.62105.07 · Cited by 215 · cited 1×
“Compared to the general population, the risk of developing cardiovascular illness is doubled and more than five times higher for endocrine disease [12,14].”
Background
Metabolic issues and cardiovascular disease in patients with psychiatric disorders
Casey, D. E. (2005) · The American Journal of Medicine Supplements · doi:10.1016/j.amjmed.2005.01.046 · Cited by 214 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study.
Hert, M. A. F. D., van Winkel, R., Eyck, D. V., Hanssens, L. S., Wampers, M., Scheen, A. J., & Peuskens, J. (2006) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-2-14 · Cited by 209
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
Zipursky, R. B., Gu, H., Green, A. I., Perkins, D. O., Tohen, M. F., McEvoy, J. P., Strakowski, S. M., Sharma, T., Kahn, R. S., Gur, R. E., et al. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.6.537 · Cited by 206 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine
Tollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder
Quiroz, J. A., Yatham, L. N., Palumbo, J. M., Karcher, K., Kushner, S., & Kusumakar, V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.015 · Cited by 200 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)
Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Nussbaum, A. M., Lieberman, J. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111609 · Cited by 200 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease
Breier, A. F., Sutton, V. K., Feldman, P. D., Kadam, D. L., Ferchland, I., Wright, P., & Friedman, J. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01392-6 · Cited by 198 · cited 1×
“One paper was treated as two separate studies, as it presented two separate data sets in a single paper [37].”
Method
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease
Deyn, P. P. D., Carrasco, M. M., Deberdt, W. G., Jeandel, C., Hay, D. P., Feldman, P. D., Young, C. A., Lehman, D. L., & Breier, A. F. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1032 · Cited by 198 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Obesity among individuals with serious mental illness
Dickerson, F., Brown, C. H., Kreyenbuhl, J. A., Fang, L., Goldberg, R. W., Wohlheiter, K. A., & Dixon, L. B. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00637.x · Cited by 198 · cited 1×
“Patients with SMI have an increased risk for metabolic problems like obesity [9,53,54].”
Background
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
Chue, P. S., Eerdekens, M., Augustyns, I., Lachaux, B., Molčan, P., Eriksson, L., Pretorius, H., & David, A. S. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.07.003 · Cited by 197 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia
Kane, J. M., Detke, H. C., Naber, D., Sethuraman, G., Lin, D., Bergstrom, R. F., & McDonnell, D. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.07081221 · Cited by 196 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight effects associated with antipsychotics: A comprehensive database analysis
Parsons, B., Allison, D. B., Loebel, A. D., Williams, K., Giller, E. L., Romano, S. J., & SIU, C. O. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.025 · Cited by 193 · cited 5×
“In firstepisode schizophrenia patients, weight gain was more prominent compared to chronic patients [24].”
BackgroundMethodResultInfluential
Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol
Smulevich, A. B., Khanna, S., Eerdekens, M., Karcher, K., Kramer, M., & Grossman, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.06.003 · Cited by 192 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Lurasidone in the Treatment of Acute Schizophrenia
Nakamura, M., Ogasa, M., Guarino, J. J., Phillips, D., Severs, J. M., Cucchiaro, J. B., & Loebel, A. D. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04905 · Cited by 191
A 3‐week, randomized, placebo‐controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states
McIntyre, R. S., Cohen, M., Zhao, J., Alphs, L. D., Macek, T. A., & Panagides, J. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00748.x · Cited by 190 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association
Czobor, P., Volavka, J., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00003 · Cited by 185 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder
van Winkel, R., Binder, M. D., Eyck, D. V., Hanssens, L., Wampers, M., Scheen, A. J., & Peuskens, J. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00520.x · Cited by 185
A Double-Blind Comparative Study of Clozapine and Risperidone in the Management of Severe Chronic Schizophrenia
Azorin, J., Spiegel, R., Remington, G. J., Vanelle, J. M., Péré, J.-J., Giguere, M., & Bourdeix, I. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1305 · Cited by 179 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia
Meltzer, H. Y., Bobo, W. V., Roy, A., Jayathilake, K., Aygun, C., Elif, E. A., Yağcioğlu, A. E. A., & Small, J. G. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0214 · Cited by 176 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Tolerability of Asenapine in Acute Schizophrenia
Potkin, S. G., & Cohen, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1004 · Cited by 175 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder
Simpson, G. M., Glick, I. D., Weiden, P. J., Romano, S. J., & SIU, C. O. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1837 · Cited by 170 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
Peuskens, J., Bech, P., Möller, H., Bale, R., Fleurot, O., & Rein, W. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00075-x · Cited by 170 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study
Keck, P. E., Orsulak, P. J., Cutler, A. J., Sanchez, R., Torbeyns, A. F., Marcus, R. N., McQuade, R. D., & Carson, W. H. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.05.014 · Cited by 169 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Thomas, S., Capuano, G. A., Rosenheck, R. A., Keefe, R. S. E., Miller, A. L., Belz, I., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.415 · Cited by 169 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression
Suppes, T. M., Datto, C. J., Minkwitz, M. C., Nordenhem, A., Walker, C., & Darko, D. F. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.10.007 · Cited by 169 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Versus Placebo in the Treatment of Borderline Personality Disorder
Bogenschutz, M. P., & Nurnberg, H. G. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0118 · Cited by 168 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Obesity, serious mental illness and antipsychotic drugs
Holt, R. I. G., & Peveler, R. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01038.x · Cited by 166 · cited 2×
“In SMI patients, overweight and obesity are more prevalent compared to the general population [9], whilst risk of developing cardiovascular diseases is substantially increased [9,10].”
Background
Association Between Early and Rapid Weight Gain and Change in Weight Over One Year of Olanzapine Therapy in Patients with Schizophrenia and Related Disorders
Kinon, B. J., Kaiser, C. J., Ahmed, S., Rotelli, M. D., & Kollack‐Walker, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000161501.65890.22 · Cited by 164 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial
McIntyre, R. S., Cohen, M., Zhao, J., Alphs, L. D., Macek, T. A., & Panagides, J. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.12.028 · Cited by 163
A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
Pandina, G., Lane, R., Gopal, S., Gassmann-Mayer, C., Hough, D. W., Remmerie, B. M. M., & Simpson, G. M. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.008 · Cited by 162 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine in the treatment of post-traumatic stress disorder: a pilot study
Butterfield, M. I., Becker, M. E., Connor, K. M., Sutherland, S. M., Churchill, L. E., & Davidson, J. R. T. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200107000-00003 · Cited by 160 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia
Meltzer, H. Y., Bobo, W. V., Nuahmah, I. F., Lane, R., Hough, D. W., Kramer, M. L., & Eerdekens, M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0515 · Cited by 158 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Managing Weight Gain and Metabolic Issues in Patients Treated With Atypical Antipsychotics
Henderson, D. C. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0208e04 · Cited by 158 · cited 1×
“Overweight and particularly obesity predicts cardiovascular risk, metabolic syndrome (MS) and diabetes mellitus type 2 (DM-II) [1–5] as well as an increased risk for cancer [6,7].”
Background
Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht, S., Kissling, W., & Davis, J. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005455 · Cited by 158 · cited 1×
“Particularly clozapine and olanzapine were associated with severe weight gain, whereas aripiprazole and ziprasidone appeared almost weight neutral [5,20,23,24,26–31].”
Background
Olanzapine in the Treatment of Pathological Gambling
McElroy, S. L., Nelson, E. B., Welge, J. A., Kaehler, L. A., & Keck, P. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0314 · Cited by 157
A 28-Week Comparison of Ziprasidone and Haloperidol in Outpatients With Stable Schizophrenia
Hirsch, S. R., Kissling, W., Bäuml, J., Power, A., & O'Connor, R. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0609 · Cited by 152 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease
Deyn, P. P. D., Jeste, D. V., Swanink, R., Kostic, D., Breder, C. D., Carson, W. H., & Iwamoto, T. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000178415.22309.8f · Cited by 150 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Bitter, I., Dossenbach, M. R. K., Brook, S., Feldman, P. D., Metcalfe, S., Gagiano, C. A., Füredi, J., Bartkó, G., Janka, Z., Bánki, C. M., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.033 · Cited by 147 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever
Kluge, M., Schuld, A., Schacht, A., Himmerich, H., Dalal, M. A., Wehmeier, P. M., Hinze-Selch, D., Kraus, T., Dittmann, R. W., & Pollmächer, T. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.08.016 · Cited by 146 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression
Ballenger, J. C. (2011) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/j.ypsy.2010.10.088 · Cited by 146
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine
Chrzanowski, W., Marcus, R. N., Torbeyns, A. F., Nyilas, M., & McQuade, R. D. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0564-3 · Cited by 145
A Randomized, Double-Blind, Placebo-Controlled Trial of Olanzapine in the Treatment of Trichotillomania
Ameringen, M. V., Mancini, C., Patterson, B. A., Bennett, M., & Oakman, J. M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05114gre · Cited by 145
Results of phase 3 of the CATIE schizophrenia trial
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Thomas, S., Swartz, M. S., Keefe, R. S. E., Miller, A. L., Rosenheck, R. A., & Hsiao, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.011 · Cited by 141 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study
Bobes, J., Rejas, J., García-García, M., Rico‐Villademoros, F., García‐Portilla, M. P., Fernández, I., & Hernández, G. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00431-0 · Cited by 140 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
Revicki, D. A., Genduso, L. A., Hamilton, S. H., Ganoczy, D. A., & Beasley, C. M. (1999) · Quality of Life Research · doi:10.1023/a:1008958925848 · Cited by 137
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis
Strassnig, M., Miewald, J. M., Keshavan, M. S., & Ganguli, R. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.02.024 · Cited by 135 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine
Newcomer, J. W., Campos, J. A. D. O., Marcus, R. N., Breder, C. D., Berman, R., Kerselaers, W., L'Italien, G. J., Nys, M., Carson, W. H., & McQuade, R. D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0702 · Cited by 131 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of Switching to Ziprasidone for Stable but Symptomatic Outpatients With Schizophrenia
Weiden, P. J., Simpson, G. M., Potkin, S. G., & O’Sullivan, R. L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0514 · Cited by 130 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Comparison of Olanzapine and Risperidone in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients With Dementia
Deberdt, W. G., Dysken, M. W., Rappaport, S. A., Feldman, P. D., Young, C. A., Hay, D. P., Lehman, D. L., Dossenbach, M. R. K., Degenhardt, E. K., & Breier, A. F. (2005) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200508000-00012 · Cited by 129 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Hyperglycemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo
Sowell, M. O., Mukhopadhyay, N. D., Cavazzoni, P. A., Shankar, S. S., Steinberg, H. O., Breier, A. F., Beasley, C. M., & Dananberg, J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8599 · Cited by 129 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Long-term use of quetiapine in elderly patients with psychotic disorders
Tariot, P. N., Salzman, C., Yeung, P. P., Pute, J., & Rak, I. W. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80085-5 · Cited by 128 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Metabolic risk during antipsychotic treatment
Newcomer, J. W. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.12.003 · Cited by 126 · cited 1×
“Amisulpride, aripiprazole and ziprasidone were weight neutral and may even result in some weight reduction [52].”
Background
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
Haro, J. M., Suarez, D. L., Novick, D., Brown, J., Usall, J., & Naber, D. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.09.005 · Cited by 126 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study
Schulz, S. C., Zanarini, M. C., BATEMAN, A. W., Bohus, M., Detke, H. C., Trzaskoma, Q., Tanaka, Y., Lin, D., Deberdt, W. G., & Corya, S. A. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037903 · Cited by 126 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
Lauriello, J., Lambert, T., Andersen, S., Lin, D., Taylor, C. C., & McDonnell, D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0512 · Cited by 120
Amisulpride vs. Risperidone in Chronic Schizophrenia Results of a 6-month Double-blind Study
Sechter, D. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00375-5 · Cited by 120 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Rock, S. L., Woolson, S., Tohen, M. F., Tollefson, G. D., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.022 · Cited by 120
A Preliminary Study of Risperidone in the Treatment of Posttraumatic Stress Disorder Related to Childhood Abuse in Women
Reich, D. B., Winternitz, S., Hennen, J. A., Watts, T., & Stanculescu, C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1204 · Cited by 119 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia
Hosojima, H., Togo, T., Odawara, T., Hasegawa, K., Miura, S., Kato, Y., Kanai, A., Kase, A., Uchikado, H., & Hirayasu, Y. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056647 · Cited by 117
A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease
Streim, J. E., Porsteinsson, A. P., Breder, C. D., Swanink, R., Marcus, R. N., McQuade, R. D., & Carson, W. H. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318165db77 · Cited by 116 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine increases plasma ghrelin level in patients with schizophrenia
Murashita, M. M., Kusumi, I., Inoue, T., Takahashi, Y., Hosoda, H., Kangawa, K., & Koyama, T. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.05.008 · Cited by 116 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
ller, H.-J. R. M., Llorca, P., Sacchetti, E., Martin, S. D., Medori, R., & Parellada, E. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200505000-00001 · Cited by 115 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study
Kerwin, R. W., Millet, B., Herman, E., Bánki, C. M., Lublin, H., Pans, M., Hanssens, L., L'Italien, G. J., McQuade, R. D., & Beuzen, J. N. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.03.002 · Cited by 113 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight gain in antipsychotic-naive patients: a review and meta-analysis
Tarricone, I., Gozzi, B. F., Serretti, A., Grieco, D., & Berardi, D. (2009) · Psychological Medicine · doi:10.1017/s0033291709990407 · Cited by 113 · cited 8×
“Second, BMI increases after first exposure to AP from more than 1 BMI point after 4–8 weeks, to almost 4 BMI points after 24–48 weeks [26].”
BackgroundMethodResultInfluential
An Open-Label Study of the Treatment Efficacy of Olanzapine for Tourette's Disorder
Budman, C. L., GAYER, A. I., LESSER, M. L., Shi, Q., & BRUUN, R. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0412 · Cited by 111 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial
Gäebel, W., Schreiner, A., Bergmans, P., de Arce, R., Rouillon, F., Cordes, J., Eriksson, L., & Smeraldi, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.111 · Cited by 111
Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Weisler, R. H., Joyce, J. M., McGill, L., Lazarus, A. L., Szamosi, J., Eriksson, H., & Moonstone Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900020307 · Cited by 109 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia
Schulz, S. C., Camlin-Shingler, K., Berry, S. A., & Jesberger, J. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00128-6 · Cited by 109 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid‐cycling disease course: a randomized, double‐blind, placebo‐controlled study
Vieta, E., Calabrese, J., Goikolea, J., Raines, S. R., Macfadden, W., & for the BOLDER Study Group (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00479.x · Cited by 109 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia
Lahti‐Pulkkinen, M., Tiihonen, J., Wildgust, H. J., Beary, M., Hodgson, R. E., Kajantie, E., Osmond, C., Räikkönen, K., & Eriksson, J. G. (2012) · Psychological Medicine · doi:10.1017/s0033291712000396 · Cited by 108 · cited 1×
“People with a diagnosis of schizophrenia have a 2–3 times increased standard mortality ratio, for all causes of death [11–13].”
Background
A Randomized Controlled Trial of Olanzapine Versus Haloperidol in the Treatment of Primary Negative Symptoms and Neurocognitive Deficits in Schizophrenia
Lindenmayer, J., Khan, A., Iskander, A., Abad, M. T., & Parker, B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0303 · Cited by 108 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study
Young, A. H., Oren, D. A., Lowy, A., McQuade, R. D., Marcus, R. N., Carson, W. H., Spiller, N. H., Torbeyns, A. F., & Sanchez, R. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.049965 · Cited by 105 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A 12-Week Randomized Clinical Trial to Evaluate Metabolic Changes in Drug-Naive, First-Episode Psychosis Patients Treated With Haloperidol, Olanzapine, or Risperidone
Pérez‐Iglesias, R., & Crespo‐Facorro, B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1113 · Cited by 104 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Single-Blind, Randomized Trial Comparing Quetiapine and Haloperidol in the Treatment of Tardive Dyskinesia
Emsley, R. A., Turner, H. J., Schronen, J., Botha, K., Smit, R., & Oosthuizen, P. P. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0516 · Cited by 104
A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia
Gopal, S., Vijapurkar, U., Lim, P., Ma, M., Eerdekens, M., & Hough, D. W. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110372817 · Cited by 103
A Naturalistic Comparison of Clozapine, Risperidone, and Olanzapine in the Treatment of Bipolar Disorder
Guille, C., Sachs, G. S., & Ghaemi, S. N. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0907 · Cited by 103 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Double-Blind, Randomized Comparative Study of Aripiprazole and Olanzapine in Patients with Schizophrenia
Fleischhacker, W. W., McQuade, R. D., Marcus, R. N., Archibald, D., Swanink, R., & Carson, W. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.07.033 · Cited by 103 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Randomized double blind comparison of olanzapine vs. clozapine on subjective well‐being and clinical outcome in patients with schizophrenia
Naber, D., Riedel, M. J., Klimke, A., Vorbach, E.-U., Lambert, M., Kühn, K. ‐., Bender, S., Bandelow, B., Lemmer, W., Moritz, S., et al. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00486.x · Cited by 102 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Thomas, S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., DAVIS, C. E., Severe, J. B., et al. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.4.539 · Cited by 102
International Multisite Double-Blind Trial of the Atypical Antipsychotics Risperidone and Olanzapine in 175 Elderly Patients With Chronic Schizophrenia
Jeste, D. V., Barak, Y., Madhusoodanan, S., Grossman, F., & Gharabawi, G. M. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200311000-00008 · Cited by 102
Asenapine for long-term treatment of bipolar disorder: A double-blind 40-week extension study
McIntyre, R. S., Cohen, M., Zhao, J., Alphs, L. D., Macek, T. A., & Panagides, J. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.04.005 · Cited by 101 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins
Starrenburg, F. C. J., & Bogers, J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.001 · Cited by 100 · cited 2×
“In addition, certain diagnoses like schizophrenia and to lesser extent bipolar disorder have been associated with a higher level of metabolic dysregulation [32] and weight gain may be more substantial in this group of patients.”
Background
Long-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder
Sanger, T. M., Grundy, S. L., Gibson, P. J., Namjoshi, M. A., Greaney, M. G., & Tohen, M. F. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0410 · Cited by 99
Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder
Kinon, B. J., Volavka, J., Stauffer, V. L., Edwards, S., Liu‐Seifert, H., Chen, L., Adams, D. H., Lindenmayer, J., McEvoy, J. P., Buckley, P. F., et al. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817e63a5 · Cited by 97 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20mg/day for the treatment of patients with acute exacerbations of schizophrenia
McEvoy, J. P., Daniel, D. G., Carson, W. H., McQuade, R. D., & Marcus, R. N. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.05.002 · Cited by 96 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Versus Risperidone in the Treatment of Manic or Mixed States in Bipolar I Disorder
Perlis, R. H., Baker, R. W., Zarate, C. A., Brown, E. B., Schuh, L. M., Jamal, H. H., & Tohen, M. F. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1112 · Cited by 95
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization
Potkin, S. G., Gharabawi, G. M., Greenspan, A. J., Mahmoud, R. A., Kosik‐Gonzalez, C., Rupnow, M. F. T., Bossie, C. A., Davidson, M., Burtea, V., & ZHU, Y. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.027 · Cited by 95
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6‐month double‐blind controlled clinical trial
Lecrubier, Y., Quintin, P., Bouhassira, M., Perrin, E., & Lancrenon, S. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00887.x · Cited by 95
Safety Profile of Iloperidone
Weiden, P. J., Cutler, A. J., Polymeropoulos, M. H., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181694f5a · Cited by 94 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Obesity in Patients With Severe Mental Illness
McElroy, S. L. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7075su1c.03 · Cited by 93 · cited 1×
“Patients with SMI have an increased risk for metabolic problems like obesity [9,53,54].”
Background
Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis
Emsley, R. A., Medori, R., Koen, L., Oosthuizen, P., Niehaus, D. J. H., & Rabinowitz, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318167269d · Cited by 91
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Jones, B. S., Basson, B. R., Walker, D. J., Crawford, A. M., & Kinon, B. J. (2001) · PubMed · Cited by 89
Quetiapine: An Effective Antipsychotic in First-Episode Schizophrenia Despite Only Transiently High Dopamine-2 Receptor Blockade
Tauscher‐Wisniewski, S., Kapur, S., Tauscher, J. T., Jones, C., Daskalakis, Z. J., Papatheodorou, G. N., Epstein, I., Christensen, B. K., & Zipursky, R. B. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1106 · Cited by 88 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Safety of Aripiprazole in the Acute Treatment of Schizophrenia in Chinese Patients With Risperidone as an Active Control
Chan, H., Lin, W., Lin, S., Hwang, T., Su, T.-P. T., Chiang, S.-C., & Hwu, H. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0104 · Cited by 88 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse
Beasley, C. M., Sutton, V. K., Hamilton, S. H., Walker, D. J., Dossenbach, M. R. K., Taylor, C. C., Alaka, K., Bykowski, D., & Tollefson, G. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095348.32154.ec · Cited by 87 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia
Kim, D. H., Maneen, M. J., & Stahl, S. M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.020 · Cited by 87 · cited 1×
“AP medication induces changes in appetite and food intake, most likely because of interaction with serotonergic [32], histaminergic [33] and dopaminergic [34] neurotransmitter systems inducing increase in appetite and food intake.”
Background
The impact upon extra‐pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia
Ritchie, C. W., Chiu, E., Harrigan, S., Hall, K., Hassett, A. M., Macfarlane, S., Mastwyk, M., O’Connor, D., Opie, J., & Ames, D. J. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.862 · Cited by 87 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight Considerations in Psychotropic Drug Prescribing and Switching
Hasnain, M., & Vieweg, W. V. R. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.09.2706 · Cited by 86 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Diabetes and schizophrenia – effect of disease or drug? Results from a randomized, double‐blind, controlled prospective study in first‐episode schizophrenia
Saddichha, S., Manjunatha, N., Ameen, S., & Akhtar, S. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01158.x · Cited by 86
Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder
Schoemaker, J. H., Naber, D., Vrijland, P., Panagides, J., & Emsley, R. (2010) · Pharmacopsychiatry · doi:10.1055/s-0030-1248313 · Cited by 84
Six-Month, Blinded, Multicenter Continuation Study of Ziprasidone Versus Olanzapine in Schizophrenia
Simpson, G. M., Weiden, P. J., Pigott, T., Murray, S., SIU, C. O., & Romano, S. J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1535 · Cited by 83 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A 24-Week Randomized Study of Olanzapine Versus Ziprasidone in the Treatment of Schizophrenia or Schizoaffective Disorder in Patients with Prominent Depressive Symptoms
Kinon, B. J., Lipkovich, I. A., Edwards, S. B., Adams, D. H., Ascher‐Svanum, H., & Siris, S. G. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000204137.82298.06 · Cited by 83
A Dose Comparison of Olanzapine for the Treatment of Borderline Personality Disorder
Zanarini, M. C., Schulz, S. C., Detke, H. C., Tanaka, Y., Zhao, F., Lin, D., Deberdt, W. G., Kryzhanovskaya, L. A., & Corya, S. A. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04138yel · Cited by 83 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of second generation antipsychotics: A systematic review of randomized trials
Johnsen, E., & Jørgensen, H. A. (2008) · BMC Psychiatry · doi:10.1186/1471-244x-8-31 · Cited by 83 · cited 1×
“Particularly clozapine and olanzapine were associated with severe weight gain, whereas aripiprazole and ziprasidone appeared almost weight neutral [5,20,23,24,26–31].”
Background
Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia
Kinon, B. J., Hill, A. L., Liu, H., & Kollack‐Walker, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003389 · Cited by 82 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs
Theisen, F., Gebhardt, S., Haberhausen, M., Heinzel‐Gutenbrunner, M., Wehmeier, P. M., Krieg, J.-C., hnau, W. K., Schmidtke, J., Remschmidt, H., & Hebebrand, J. (2005) · Psychiatric Genetics · doi:10.1097/00041444-200512000-00011 · Cited by 82 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies
Emsley, R. A., Berwaerts, J., Eerdekens, M., Kramer, M. L., Lane, R., Lim, P., Hough, D., & Palumbo, J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328314e1f3 · Cited by 81 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone
Lasser, R. A., Bossie, C. A., Gharabawi, G. M., & Turner, M. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2003.11.007 · Cited by 81
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder
Keks, N. A., Ingham, M., Khan, A., & Karcher, K. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.017020 · Cited by 81 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study☆
Bortnick, B., El-Khalili, N., Banov, M. D., Adson, D. E., Datto, C. J., Raines, S. R., Earley, W. R., & Eriksson, H. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.031 · Cited by 80 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized Placebo-Controlled Trial of Asenapine for the Prevention of Relapse of Schizophrenia After Long-Term Treatment
Kane, J. M., Mackle, M., Snow‐Adami, L., Zhao, J., Szegedi, A., & Panagides, J. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06306 · Cited by 80 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
International Multisite Double-Blind Trial of the Atypical Antipsychotics Risperidone and Olanzapine in 175 Elderly Patients With Chronic Schizophrenia
Jeste, D. V. (2003) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.11.6.638 · Cited by 80 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications
Beary, M., Hodgson, R., & Wildgust, H. J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112440512 · Cited by 79 · cited 1×
“Overweight and particularly obesity predicts cardiovascular risk, metabolic syndrome (MS) and diabetes mellitus type 2 (DM-II) [1–5] as well as an increased risk for cancer [6,7].”
Background
Clinical outcome and olanzapine plasma levels in acute schizophrenia
Mauri, M. C., Steinhilber, C. P. C., Marino, R., Invernizzi, E., Fiorentini, A., Cerveri, G., Baldi, M., & Barale, F. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.09.009 · Cited by 76 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Tolerability of Ziprasidone Versus Risperidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
Addington, D. E., Pantelis, C., Dineen, M., Benattia, I., & Romano, S. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1207 · Cited by 75
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
Ascher‐Svanum, H., Stensland, M. D., Zhao, Z., & Kinon, B. J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-3 · Cited by 74 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol
KRAKOWSKI, M. I., Czobor, P., & Citrome, L. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.006 · Cited by 74 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Safety and Efficacy of Long-Acting Risperidone in Schizophrenia
Lindenmayer, J., Eerdekens, E., Berry, S. A., & Marielle, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0809 · Cited by 74 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
The Apparent Effects of Ziprasidone on Plasma Lipids and Glucose
Kingsbury, S. J., Fayek, M., Trufasiu, D., Zada, J., & Simpson, G. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0507 · Cited by 73 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine vs. other antipsychotics in actual out‐patient settings: six months tolerability results from the European Schizophrenia Out‐patient Health Outcomes study
Lambert, M., Haro, J. M., Novick, D., Edgell, E. T., Kennedy, L., Ratcliffe, M., & Naber, D. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00451.x · Cited by 72 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Strategies for Switching From Conventional Antipsychotic Drugs or Risperidone to Olanzapine
Kinon, B. J., Basson, B. R., Gilmore, J. A., Malcolm, S. K., & Stauffer, V. L. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1105 · Cited by 70 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Quetiapine for the treatment of bipolar mania in older adults
Sajatovic, M., Calabrese, J. R., & Mullen, J. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00614.x · Cited by 70 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapineversushaloperidol in the treatment of schizoaffective disorder
Trân, P. V., Tollefson, G. D., Sanger, T. M., Lu, Y., Berg, P. H., & Beasley, C. M. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.174.1.15 · Cited by 69
Effects of long-term treatment with antipsychotics on serum leptin levels
Herrán, A., García‐Unzueta, M. T., Amado, J., Maza, M. T. D. L., Álvarez, C. F., & Vázquez‐Barquero, J. L. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.1.59 · Cited by 69 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety
Sheehan, D. V., McElroy, S. L., Harnett-Sheehan, K., Keck, P. E., Janavs, J., Rogers, J., Gonzalez, R., Shivakumar, G., & Suppes, T. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.005 · Cited by 69 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Use of Ziprasidone in Parkinsonian Patients With Psychosis
Gómez‐Esteban, J. C., Zarranz, J. J., Velasco, F., Lezcano, E., Lachen, M. C., Rouco, I., Bárcena, J., Boyero, S., Ciordia, R., & Allue, I. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000164297.91643.ff · Cited by 68 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Quetiapine Alone and Added to a Mood Stabilizer for Serious Mood Disorders
Sajatovic, M., Brescan, D. W., Perez, D. E., DiGiovanni, S. K., Hattab, H., Belton, J., & Bingham, C. R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0911 · Cited by 68 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
The Early Effect of Olanzapine and Risperidone on Insulin Secretion in Atypical-naïve Schizophrenic Patients
Chiu, C.-C., Chen, K.-P., Liu, H.-C., & Lu, M. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000237947.80764.d9 · Cited by 67
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling
Sanger, T. M., Tohen, M. F., Vieta, E., Dünner, D. L., Bowden, C. L., Calabrese, J. R., Feldman, P. D., Jacobs, T. G., & Breier, A. F. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00334-8 · Cited by 67 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A 28-Week, Randomized, Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia
Kane, J. M., Osuntokun, O. O., Kryzhanovskaya, L. A., Xu, W. R., Stauffer, V. L., Watson, S. B., & Breier, A. F. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04421 · Cited by 66 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study
Sacchetti, E., Galluzzo, A., Valsecchi, P., Romeo, F., Gorini, B., & Warrington, L. E. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.017 · Cited by 66
Early Predictors of Substantial Weight Gain in Bipolar Patients Treated with Olanzapine
Lipkovich, I. A., Citrome, L., Perlis, R. H., Deberdt, W. G., Houston, J., AHL, J. S. B., & Hardy, T. A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000219916.88810.1c · Cited by 65
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
Kane, J. M., Khanna, S., Rajadhyaksha, S., & Giller, E. L. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182114.65134.81 · Cited by 65
Comparison of Quetiapine and Risperidone in the Treatment of Schizophrenia
Zhong, K., Sweitzer, D. E., Hamer, R. M., & Lieberman, J. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0712 · Cited by 65 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study
Olié, J., Spina, E., Murray, S., & Yang, R. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182121.59296.70 · Cited by 64
Risperidone, Quetiapine, and Fluphenazine in the Treatment of Patients With Therapy-Refractory Schizophrenia
Conley, R. R., Kelly, D. L., Nelson, M. W., Richardson, C. M., Feldman, S. M., Benham, R., Steiner, P., Yu, Y., Khan, I., McMullen, R., et al. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000172993.89879.0f · Cited by 64 · cited 1×
“6 (16–38 wk, n = 9) [44], iloperidone 2.”

Research works printed but not linked: 1

P Chue, 2005, Study of long-term quetiapine treatment, The journal of applied research, 5, 246

Sorted by citations

Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity
Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline
Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,375
“Furthermore, clinicians should obtain a history of second-generation antipsychotics use, such as clozapine, risperidone, olan-zapine, and quetiapine, because of their association with weight gain (52, 53).”
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
“Where possible, medicines with the least risk of weight gain should be selected (Bak et al., 2014).”
Background
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Antipsychotic medication in schizophrenia: a review
Lally, J., & MacCabe, J. H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv017 · Cited by 560
“The most dramatic weight gain is seen in antipsychotic naïve patients over the first 6 weeks of treatment and for the majority, those with initial weight gain did not lose that weight thereafter, even after switching to more weight-neutral antipsychotics.(14) SGAs such as aripiprazole, lurasidone and asenapine have a…”
Background

See all 490

Authors: Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M.
Affiliations: Maastricht University Medical Centre (NL)
Máxima Medisch Centrum (NL)
Corresponding author: Bak, Maarten
ORCID: Bak, Maarten
Fransen, Annemarie
Drukker, Marjan
Venue: PLoS ONE
Publisher: Public Library of Science (PLoS)
Published: 2014-04-24
Volume: 9
Issue: 4
Pages: e94112
ISSN: 1932-6203 (ISSN-L)
DOI: 10.1371/journal.pone.0094112
PMC: PMC3998960
OpenAlex: W2089001223
Cited by: 490
References: 362
Citations by year: 2026: 17 · 2025: 31 · 2024: 39 · 2023: 42 · 2022: 47 · 2021: 48 · 2020: 45 · 2019: 55 · 2018: 50 · 2017: 43 · 2016: 39 · 2015: 28 · 2014: 5
FWCI: 5.28
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: PLoS ONE (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, other-oa)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Research Publications (Maastricht University) (publishedVersion, cc-by)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Figshare (submittedVersion, cc-by)
NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
Research Publications (Maastricht University) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
Keywords: antipsychotic drugs, weight gain, body mass index, antipsychotic switching, amisulpride, aripiprazole, ziprasidone, antipsychotic-naive patients, weight loss
MeSH terms: Bipolar Disorder, Humans, Schizophrenia, Antipsychotic Agents, Weight Gain, Body Mass Index, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks